Shanghai KeChow Pharmaceuticals

Shanghai KeChow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for the treatment of cancer and other life-threatening diseases. The company's lead candidate, tunlametinib (HL-085), is a potent and selective MEK inhibitor that has received marketing approval in China for the treatment of NRAS-mutant advanced melanoma. KeChow's pipeline also includes several other targeted therapies aimed at the MAPK pathway and other oncogenic drivers. The company leverages its expertise in medicinal chemistry to develop best-in-class or first-in-class therapies with improved safety and efficacy profiles. In March 2024, the company successfully listed on the Shanghai Stock Exchange STAR Market.